DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Firms / P•••••••• H••••••••• C•••••• M••••••••• L•
P•••••••• H••••••••• C•••••• M••••••••• L•
Classification
- Class
- Buyout firmconfirmed, confidence 85%
- Basis
- R6: 3 of 4 distinct vehicles are sworn Private Equity Funds; 3 reported gross assets on a filing in 2022 or later
- Size band
- Lower middle marketdefined by: proxy: $0.59bn Private Equity Fund GAV on the Form ADV filed 2024-09-30
Classification history (1)
- Sep 13, 2026Buyout firm (confirmed, 85%, cls-pe-1)R6: 3 of 4 distinct vehicles are sworn Private Equity Funds; 3 reported gross assets on a filing in 2022 or later
Regulatory footprint (Form ADV)
- Adviser type
- registered investment adviser
- Form ADV filings
- Jul 14, 2017 to Sep 30, 2024
- RAUM
- $872Mregulatory assets under management of the adviser; not dry powder, not a fund size
- PE funds, latest filing
- 3
- PE fund GAV, latest filing
- $591Mreported gross assets (Form ADV), not fund size
- All private fund GAV
- $872Mevery private fund type, latest filing
- 2024 PE fund GAV
- $591Msum over funds typed Private Equity Fund with a 2024 or later as-of date
- PE share of funds, lifetime
- 75%
- Fund type mix
- filed 2024-09-30, latest gav Private Equity Fund $591M, Venture Capital Fund $281M, latest counts Private Equity Fund 3, Venture Capital Fund 1, lifetime distinct Private Equity Fund 3, Venture Capital Fund 1
- Employees
- 15
- Headquarters
- New York, NY
- Office address
- 220 EAST 42ND STREET, 37TH FLOOR, New York, NY, 10017
- Business phone
- 646-443-6606
Stated criteria beside observed behaviour
22 observed deals
Stated by the firm
- Sectors
- not stated or not yet read
- Geography
- not stated or not yet read
- Revenue
- not stated or not yet read
- EBITDA
- not stated or not yet read
- Enterprise value
- not stated or not yet read
- Equity check
- not stated or not yet read
- Control
- not stated or not yet read
- Thesis
- not stated or not yet read
Observed from deals on record
- roles
- add on 2, unknown 19, platform 2
- period
- to 2024-03-27, from 2018-12-17, undated holdings 20, dated observations 6
- window
- last 2024-03-27, first 2018-12-17
- control
- control 3, unknown 20
- companies
- 22
- geography
- investments
- 23
- seller kinds
- transactions
- 3
- cadence by year
- 2018 platforms 1, 2024 add ons 2
- platform add on
- add ons 2, platforms 2, add ons per platform unknown
- sector known for
- 1
- disclosed value usd
- n 0
- sector distribution
- count 1, share 0.045, value agriculture, examples Avalo
- holding period years
- n 0
- repeat counterparties
- role legal adviser, shared 2, entity id a7ba7dc3-4fb6-414a-9ff2-a8e19d5c9b50, role legal adviser, shared 2, entity id 558c18bc-c82d-4243-b126-551afec7f423
- subsector distribution
- count 1, share 0.045, value agriculture, examples Avalo
22 companies on the graph (3 transactions); most in agriculture (1); 2 platforms and 2 add-ons; observed 2018 to 2024
Funds
5 on record
| Fund | Vehicle | Vintage | Reported gross assets (Form ADV), not fund size | GAV by year | Form D sold | Lifecycle |
|---|---|---|---|---|---|---|
| P•• I• C••••••• L• ADV: Private Equity Fund | Co-investment vehicle | 2022 first reported on Form ADV | $101M as of Sep 30, 2024 | no Form D | Early deployment | |
| P•••••••• O••••••••• F••• I• I••••••••• L• ADV: Private Equity Fund | Feeder or parallel | 2021 first reported on Form ADV | $151M as of Sep 30, 2024 | no Form D | Unknown | |
| P•••••••• O••••••••• F••• I• L• ADV: Private Equity Fund | buyout or unlabelled | unknown | $339M as of Sep 30, 2024 | no Form D | Mature | |
| P•••••••• H••••••••• F••• I• | buyout or unlabelled | unknown | unknown | no reporting | no Form D | Unknown |
| P•••••••• H••••••••• F••• I• | buyout or unlabelled | unknown | unknown | no reporting | no Form D | Unknown |
Team
22 current, 1 former
Managing partner (5)
- A•••• K•••••• · Founder, Managing Partner S•••• · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- S••••• H•••• P•• · Founder, Managing Partner S•••• · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T••• S••••• W••••• · Founder and Managing Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T••• S••••• W••••• · Managing Member · since Nov 1, 2016 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- T••• W••••• · Founder and Managing Partner · start date unknown Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)
Partner (3)
- A•••••• L•••• P•• · Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- M•••••• B•••••• · Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- P•••••• L•••• · Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Principal (1)
- M•••• B•••••• · Principal · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Vice president (1)
- L••• B•••• · Senior Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Associate (4)
- A••••• D•••• · Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- E••••• W•••••• P•• · Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- S••••• H•••••• P•• · Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T••••• L••••••• · Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Operating partner (2)
- D•• H••••••• · P•••••••• Operating Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- P••• S••••• · P•••••••• Operating Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Business development (1)
- D•••• K••••• · Head of Business Development & Investor Relations · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Platform (3)
- E•••• H•••••• · Director of Finance · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- J•••••• E•••••• · Chief Compliance Officer · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- M•••••• L••••••••• · Executive Assistant · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Other (2)
- P•••• S• G•••••••• · Advisor · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- W••••• C•••• · MD, PhD · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
1 former (kept with end dates)
- B••••• M••••••• S••••• K••••••• · Chief Financial Officer And Chief Compliance Officer · Mar 1, 2020 to Sep 30, 2024 Inference
Portfolio
23 relationships, 2 platforms, 2 add-ons
Transactions
3 on record
| Date | Type | Target | This firm’s role | Source |
|---|---|---|---|---|
| Mar 27, 2024 | Add-on acquisition | P•••• 2•••••• | Sponsor (derived) | ir.avalotx.com |
| Mar 27, 2024 | Add-on acquisition | P•••• 2•••••• | Sponsor (derived) | ir.avalotx.com |
| Dec 17, 2018 | Platform acquisition | C••••••• | Sponsor (confirmed) | prnewswire.com |
Placement agents, lenders, advisers and co-investors
7 relationships
Placement agents (3)
- M••••• • C•••••• L•• 2 shared · recurring · last Jan 1, 2021
- W••••••• P••••••• L•• 1 shared · one time · last Jan 1, 2019
- P••••• A••••••• 1 shared · one time · last Jan 1, 2019
Legal advisers (4)
- S•••••• R••• • Z•••• L•• 2 shared · recurring · last Mar 27, 2024
- G•••••• P•••••• 2 shared · recurring · last Mar 27, 2024
- W••••• R•••••• Y•••• • P••••• L•• 1 shared · one time · last Mar 27, 2024
- W••••• R•••••• Y•••• • P••••• L•• 1 shared · one time · last Mar 27, 2024
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
32 most recent
- Sep 16, 2026P••••••• Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt P•••s, J.D., M.B.A., to Board of Directors June 2026 Read more on
- Sep 16, 2026P•••••••• Names Diagnostics Industry Leader D•• H••••••• as Operating Partner May 2026 Read more on
- Sep 16, 2026P•••••••• Names P••• S••••• as Operating Partner April 2026 Read more on
- Sep 16, 2026E••••• Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency January 2026 Read more on
- Sep 16, 2026T••••••••• Bio Enters into Agreement to be Acquired by Novartis AG September 2025 Read more on
- Sep 16, 2026Alcon Acquires Majority Interest in A••••• Biotech, Inc. to Advance Innovative C••• Therapy for C•••••l Endothelial Disease March 2025 Read more on
- Sep 16, 2026G••••••••• Closes $105M in Series C Funding Round to Power Next-G•••ration of Gastrointestinal Diagnostic Tests January 2025 Read more on
- Sep 16, 2026P••••••• Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million December 2024 Read more on
- Sep 16, 2026A••••• Advanced T•••••••• Partners with EW H••••••••• Partners to Expand United States Capacity and Capabilities November 2024 Read more on
- Sep 16, 2026P••••••• Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement July 2024 Read more on
- Sep 16, 2026E•••••••• T••••••••• Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services April 2024 Read more on
- Sep 16, 2026A••••• acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production April 2024 Read more on
- Sep 16, 2026A•••• Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million March 2024 Read more on
- Sep 16, 2026F••••• announces incremental $5 million investment from P•••••••• December 2023 Read more on
- Sep 16, 2026T••••••••• Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million October 2023 Read more on
- Sep 16, 2026ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities June 2023 Read more on
- Sep 16, 2026F••••• Pharmaceuticals Announces Second Closing of $20 Million Investment from P•••••••• September 2022 Read more on F••••• Pharmaceuticals
- Sep 16, 2026F••••• Pharmaceuticals Announces Up to $45 Million Investment From P•••••••• August 2022 Read more on F••••• Pharmaceuticals
- Sep 16, 2026P•••••••• Managing Partner T••• W••••• Joins the ICPO Foundation Board of Curators May 2022 Read more on ICPO
- Sep 16, 2026LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA H••••••••• Acquisition Corp. September 2021 Read more on LumiraDx
- Sep 16, 2026P•••••••• Closes Oversubscribed Fund I at $410 Million November 2020
- Sep 16, 2026Blackstone invests $275 million in C••••••• to fund acquisition of MVE Biological Solutions October 2020 Read more on Cision
- Sep 16, 2026MRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and P•••••••• H••••••••• Capital Management January 2020 Read more on C••••••••• N••••
- Sep 16, 2026C••••••• Announces $25 Million Investment from P•••••••• H••••••••• Capital Management December 2018 Read more on Cision
- Apr 1, 2025Lantheus Completes Acquisition of E•••••••• T••••••••• April 2025 Read more on
- Jan 28, 2025Lantheus to Acquire E•••••••• T••••••••• for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader January 2025 Read more on
- Aug 5, 2024F••••• Pharmaceuticals Appoints J•••••• S. Hackman as Chief Executive Officer and Director August 2024 Read more on
- Jun 27, 2024T••••••••• Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer June 2024 Read more on
- Jun 20, 2024ITM Appoints Dr. A••••• Cavey as CEO to Lead Organization in its Next Stage of Growth June 2024 Read more on
- May 7, 2024ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer May 2024 Read more on
- Dec 17, 2018C••••••• Announces $25 Million Investment from P•••••••• H••••••••• Capital ManagementPlatform investmentFactC•••••••Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)
- Jul 14, 2017P•••••••• H••••••••• C•••••• M••••••••• L• first filed Form ADV in the extract (ERA)
Across the graphs
P•••••••• H••••••••• C•••••• M••••••••• L• is the same institution as 3 records in Venture Capital, Independent Sponsors and RIA and Wealth.
Venture Capital1Independent Sponsors1RIA and Wealth1
Which record it is in each graph, what it is called there, and what the two were joined on. The Data Factory holds all nine graphs and the identity layer between them.
Checking your plan…